Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smaller dose of sugammadex rescue patients when standard reversal fails?

NCT ID NCT05661409

Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested five different low doses of sugammadex (a drug that reverses muscle relaxants) in 46 adults who still had muscle weakness after the standard reversal drug neostigmine. The goal was to see how quickly each dose restored normal muscle function. If a lower dose works, it could give doctors more options and reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sugammadex
What this could lead to
If successful, this could help anesthesiologists use lower, more precise doses of sugammadex to quickly reverse muscle relaxation when the usual drug doesn't work well enough.
What could go wrong
This is a small, early-phase trial with only 46 participants, so results may not apply to all patients. Lower doses might not work as well as the standard dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

46 people

The number who actually took part.

Started

Jul 2023

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years and above who will undergo an elective surgery in the main operating room or outpatient surgery center at Grady Memorial Hospital * Receive general anesthesia (standardized to sevoflurane for maintenance) * Receive rocuronium for NMB * Receive neostigmine for NMB reversal * Achieve a TOF count of at least 3 twitches but not a TOF ratio of 0.9 fifteen minutes after neostigmine has been given * Able and willing to provide informed consent. Exclusion Criteria: * Pregnancy and/or lactating * BMI ≥ 40 * Severe renal impairment, i.e. chronic kidney disease stages IV and V as defined by GFR \< 30 ml/min/1.73 m2 * Severe hepatic impairment, i.e. Child-Pugh score C * Pre-existing neuromuscular disease * Anticipated need for postoperative intubation, and/or known hypersensitivity reactions to rocuronium, neostigmine and/or sugammadex. * Adults unable to consent * Prisoners * Cognitively impaired or Individuals with Impaired Decision-Making Capacity * Individuals who are not able to clearly understand English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuromuscular blockade are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuromuscular blockade

Contacts and locations

Locations

  • Grady Memorial Hospital

    Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.